Radionuclide-Based Theranostics
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (20 April 2022) | Viewed by 8500
Special Issue Editors
Interests: targeted radionuclide therapy; radionuclide molecular imaging; radiolabelling chemistry; scaffold proteins; antibody
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Respected Colleagues,
The theranostics paradigm consists of the possibility of labeling a molecular targeting vector (e.g., peptides or antibodies) either with diagnostic (e.g., positron or gamma-emitters) or therapeutic radionuclides (e.g., alfa, beta-emitters, or auger electron-emitters) paving the way for personalizing cancer treatment, with the possibility of using the same targeting agent for diagnostics, staging, monitoring of treatment response, and therapy. In recent years, the field of cancer theranostics has evolved considerably due to the definition of suitable biological targets and targeting strategies (e.g., SSTR- and PSMA-based concepts). The evolving development of theranostics in oncology is making the treatment of malignant diseases feasible and holds great promise for improved patient outcomes in the future.
We hereby would like to invite you to contribute to this Special Issue. Review or original research articles highlighting current progress in the development of potential targeting agents and the different aspects of theranostics will form the basis of this Special Issue on “Radionuclide-Based Theranostics”. We look forward to your contributions.
Dr. Mohamed Altai
Dr. Joanna Strand
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- theranostics
- imaging (PET, SPECT)
- nuclear medicine (preclinical and clinical)
- radionuclide therapy
- dosimetry
- drug development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.